JPJason Paragas

Jason Paragas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jason Paragas has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Aura R. Garrison

    Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, USA

    1 shared publication
  • Chris Hartmann

    Virology Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), 1425 Porter Street, Fort Detrick, MD 21702-5011, USA

    1 shared publication
  • David A Kulesh

    Diagnostic Systems Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Maryland, United States of America

    1 shared publication
  • David A Norwood

    Diagnostic Systems Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Maryland, United States of America

    1 shared publication
  • Elizabeth A Fritz

    Virology Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Maryland, United States of America

    1 shared publication
  • Elizabeth Vitalis

    Lawrence Livermore National Laboratory, Livermore, California, United States of America

    1 shared publication

Latest Publications

  • Open Access

    Cynomolgus Macaque as an Animal Model for Severe Acute Respiratory Syndrome

    by James V Lawler, Timothy P Endy, Lisa E Hensley, Aura Garrison, Elizabeth A Fritz, May Lesar, Ralph S Baric, David A Kulesh, David A Norwood, Leonard P Wasieloski, et al.

    The emergence of severe acute respiratory syndrome (SARS) in 2002 and 2003 affected global health and caused major economic disruption. Adequate animal models are required to study the underlying pathogenesis of SARS-associated coronavirus (SARS-CoV) infection and to develop effective vaccines and therapeutics. We report the first findings of measurable clinical disease in nonhuman primates (NHPs) infected with SARS-CoV. In order to characterize clinically relevant parameters of SARS-CoV infection in NHPs, we infected cynomolgus macaques with SARS-CoV in three groups: Group I was infected in the nares and bronchus, group II in the nares and conjunctiva, and group III intravenously. Nonhuman primates in groups I and II developed mild to moderate symptomatic illness. All NHPs demonstrated evidence of viral replication and developed neutralizing antibodies. Chest radiographs from several animals in groups I and II revealed unifocal or multifocal pneumonia that peaked between days 8 and 10 postinfection. Clinical laboratory tests were not significantly changed. Overall, inoculation by a mucosal route produced more prominent disease than did intravenous inoculation. Half of the group I animals were infected with a recombinant infectious clone SARS-CoV derived from the SARS-CoV Urbani strain. This infectious clone produced disease indistinguishable from wild-type Urbani strain. SARS-CoV infection of cynomolgus macaques did not reproduce the severe illness seen in the majority of adult human cases of SARS; however, our results suggest similarities to the milder syndrome of SARS-CoV infection characteristically seen in young children.


  • Open Access

    Interferon alfacon1 is an inhibitor of SARS-corona virus in cell-based models

    by Jason Paragas, Lawrence M. Blatt, Chris Hartmann, John W. Huggins, Tim P. Endy